Tissue prognostic markers for adoptive immunotherapy in melanoma

European Journal of Dermatology

Volumn 17, Issue 4, 2007, Pages 295-301

  Quereux, Gaëlle ^a,c   Pandolfino, Marie Christine ^a,c   Knol, Anne Chantal ^a,c   Khammari, Amir ^a,c   Volteau, Christelle ^a   Nguyen, Jean Michel ^b   Dreno, Brigitte ^a,b,c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

Author keywords

Immunotherapy; Lymphocyte; Melanoma; Prognostic marker; Survival; Tumour infiltrating

Indexed keywords

ALPHA INTERMEDIN; CELL ADHESION MOLECULE; CYTOKINE; GLYCOPROTEIN GP 100; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTE; MALE; MELANOCYTE; MELANOMA; MULTIVARIATE ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 34447332267     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2009.0203     Document Type: Article

References (22)

1. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukine-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319(25): 1676-80.
2. Van den Eynde BJ, Van der Bruggen P. T Cell defined tumor antigens. Curr Opin Immunol 1997; 9(5): 684-93.
3. Seledtsov VI, Shishkov AA, Surovtseva MA, et al. Xenovaccino-therapy for melanoma. Eur J Dermatol 2006; 16(6): 655-61.
4. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25(5): 243-51.
5. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99(25): 16168-73.
6. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173(2): 1444-53.
7. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity following clonal repopulation with anti-tumor lymphocytes and non-myeloablative conditioning. Science 2002; 298(5594): 850-4.
8. Woods GM, Malley RC, Muller HK. The skin immune system and the challenge of tumour immunosurveillance. Eur J Dermatol 2005; 15(2): 63-9.
9. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51(10): 539-46.
10. Labarriere N, Pandolfino MC, Gervois N, et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 2002; 51(10): 532-8.
11. Chebassier N, El Houssein O, Viegas I, Dréno B. In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol 2004; 13(8): 484-90.
12. Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother 2004; 27(1): 73-8.
13. Kageshita T, Kawakami Y, Hirai S, Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 1997; 20(6): 460-5.
14. Berset M, Cerottini JP, Guggisberg D, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer 2001; 95(1): 73-7.
15. Van Duinen SG, Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48(4): 1019-25.
16. Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 2005; 65(5): 419-28.
17. Brocker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984; 82(3): 244-7.
18. Ruiter DJ, Bergman W, Welvaart K, et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984; 44(9): 3930-5.
19. Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50(4): 1271-8.
20. Eves P, Haycock J, Layton C, et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003; 89(10): 2004-15.
21. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci 2003; 994: 133-40.
22. Nagahama M, Funasaka Y, Fernandez-Frez ML, et al. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocyte naevi. Br J Dermatol 1998; 138(6): 981-5.